Loss of Munc18-1 long splice variant in GABAergic terminals is associated with cognitive decline and increased risk of dementia in a community sample by Alfredo Ramos-Miguel et al.
RESEARCH ARTICLE Open Access
Loss of Munc18-1 long splice variant in
GABAergic terminals is associated with
cognitive decline and increased risk of
dementia in a community sample
Alfredo Ramos-Miguel1,2, Christa Hercher1,2, Clare L. Beasley1,2, Alasdair M. Barr1,3, Thomas A. Bayer4, Peter Falkai5,
Sue E. Leurgans6, Julie A. Schneider6, David A. Bennett6 and William G. Honer1,2*
Abstract
Background: Presynaptic terminals contribute to cognitive reserve, balancing the effects of age-related pathologies on
cognitive function in the elderly. The presynaptic protein Munc18-1, alternatively spliced into long (M18L) or short (M18S)
isoforms, is a critical modulator of neurotransmission. While subtle alterations in Munc18-1 have been shown to cause
severe neuropsychiatric disorders with cognitive impairment, little information is known regarding the specific roles of
Munc18-1 splice variants. We first investigated functional and anatomical features evidencing the divergent roles of M18L
and M18S, and then evaluated their contribution to the full range of age-related cognitive impairment in the dorsolateral
prefrontal cortex of a large sample of participants from a community-based aging study, including subjects with
no-(NCI, n = 90), or mild-(MCI, n = 86) cognitive impairment, or with clinical dementia (n = 132). Finally, we used
APP23 mutant mice to study the association between M18L/S and the time-dependent accumulation of common
Alzheimer’s disease pathology.
Results: Using isoform-specific antibodies, M18L was localized to the synaptosomal fraction, with a distribution matching
lipid raft microdomains. M18S was found widely across cytosolic and synaptosomal compartments. Immunocytochemical
studies identified M18L in perisomatic, GABAergic terminals, while M18S was broadly distributed in GABAergic and
glutamatergic terminals. Using regression models taking into account multiple age-related pathologies, age, education
and sex, global cognitive function was associated with the level of M18L (p = 0.006) but not M18S (p = 0.88). Mean M18L
in dementia cases was 51 % lower than in NCI cases (p < 0.001), and each unit of M18L was associated with a lower
likelihood of dementia (odds ratio = 0.68, 95 % confidence interval = 0.50–0.90, p = 0.008). In contrast, M18S balanced
across clinical and pathologically diagnosed groups. M18L loss may not be caused by age-related amyloid pathology,
since APP23 mice (12- and 22-months of age) had unchanged cortical levels of M18L/S compared with wild-type animals.
Conclusions: M18L was localized to presynaptic inhibitory terminals, and was associated with cognitive function and
protection from dementia in an elderly, community-based cohort. Lower M18L in inhibitory presynaptic terminals may
be an early, independent contributor to cognitive decline.
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Background
Common age-related neuropathologies, including
Alzheimer’s disease pathology (i.e. neuritic plaques
and neurofibrillary tangles), cerebral infarcts, and
Lewy bodies, accumulate in the human brain across
the lifetime. The susceptibility of cognitive function
to decline as growing amounts of neuropathology
develop in the forebrain varies greatly between indi-
viduals, raising the concept of cognitive reserve [1–3].
Large community-based studies have been designed,
at least in part, to investigate the biological substrates
of cognitive reserve [4–7]. The initial model that people
with mentally enriched lives may exhibit greater resistance
against brain-damaging diseases [2] is not yet supported
with clear neurochemical correlates. Synaptic pathology is
common in aging, being first reported as a deficit of
presynaptic markers [8–11]. In some studies, synaptic
pathology showed stronger association with cognitive
decline than other common age-related pathologies [12],
suggesting that intact, functional synapses may contribute
to cognitive reserve.
In this context, we previously reported that better
cognitive performance, a reduced odds of dementia,
and slower rate of cognitive decline over multiple years
prior to death were associated with greater densities of
specific presynaptic proteins, and enhanced presynaptic
protein-protein interactions (PPIs) [13, 14]. Interest-
ingly, these PPIs involved the associations between
syntaxin-1, synaptosomal-associated protein-25 (SNAP-
25), and vesicle-associated membrane protein (VAMP,
or synaptobrevin), which together assemble the machinery
facilitating vesicle trafficking and neurotransmitter release,
known as the soluble N-ethylmaleimide-sensitive factor
attachment protein receptor (SNARE) [15]. However, other
frequent targets of synaptic pathology, such as synapto-
physin, were not associated with cognitive function or
Alzheimer’s disease pathology in the same community-
based cohort study, which included subjects with the
full range of cognition from normality, to mild cogni-
tive impairment, to dementia. Of note, many of the
studies related to synaptic pathology were based on
subpopulations of hospital- or clinic-based patients
displaying moderate-to-severe degrees of dementia, not
necessarily representative of the spectrum of cognitive
decline in aging [16]. Previous analyses in mixed post-
mortem brain series found biphasic alterations of brain
presynaptic markers (including synaptophysin) across
age-related cognitive decline and/or Alzheimer’s disease
progression, with upregulated densities at intermediate
stages and reduced levels in more severe cases [17–19].
Together, these observations suggest that an initial
failure of presynaptic terminals to maintain synaptic
function (reflected by SNARE disruption) might be
compensated by upregulating the expression of certain
presynaptic genes; further accumulation of neuropathol-
ogies may result in the observed synaptic degeneration at
relatively more severe stages. The mechanisms underlying
initial SNARE and presynaptic dysfunction could be
directly linked to age-related cognitive impairment and
progression to dementia. Consistent with these observa-
tions, murine models with impaired SNARE PPIs undergo
related behavioral and physiological neurodegenerative
syndromes [20, 21].
Although the biochemical and physiological nature of
neurosecretion is well established [22–24], the association
between SNARE dysregulation and the pathophysiology of
aging-related diseases is unclear. Among the regulators
potentially involved in SNARE dysfunction, mammal unc-
18-1 (Munc18-1 or n-Sec1; herein M18) is a strong candi-
date. First identified by random mutagenesis screening for
uncoordinated phenotypes in the worm Caenorhabditis
elegans, M18 caught the attention of many research teams
when described as a ‘syntaxin-binding protein’ (coining the
M18 coding gene as STXBP1) twenty years later [25–27].
While still controversial, M18 is believed to have multiple
activities during SNARE-regulated exocytosis, which may
include trafficking and chaperoning syntaxin-1, transition
from cis-to-trans SNARE conformations, and/or docking
the presynaptic vesicle [23, 28, 29]. The observation that
STXBP1 null mice lack neocortical synaptic activity [30]
highlights the irreplaceable role of M18 for neurosecretion.
Interestingly, M18 knockout mice also exhibit massive
neuronal apoptosis and widespread neurodegeneration, and
consequently do not survive after birth [30].
In mammals, the STXBP1 gene is alternatively spliced
to yield either a long (M18L) or a short (M18S) variant
[31, 32], also called isoforms a and b, respectively. Pro-
cessing of the final exon in the STXBP1 primary tran-
script may include (M18L) or skip (M18S) a sequence of
110 bp containing a stop codon [32], resulting in two
different C-terminal amino acid sequences for M18L/S
(see Fig. 1a). To our knowledge, specific regulatory
mechanisms of STXBP1 gene splicing have not been
described. Although intensive research focuses on M18
activities in regulated exocytosis, the potentially diver-
gent roles of the M18 variants are relatively neglected,
assuming no substantial differences between them [32].
However, recent observations indicate that M18 variants
may not have overlapping functions. Transgenic mice
expressing a fluorophore-tagged, functional M18S were
generated using a replacement strategy that erased the
M18L splice variant [33, 34]. These animals show severe
physical and behavioral deficits, and die prematurely a
few weeks after birth. Conversely, mice overexpressing
M18L in both glutamatergic and GABAergic neurons
display aspects of a schizophrenia-like phenotype [35],
compatible with alterations observed in human postmor-
tem studies [36–38]. At a cellular level, transfection of
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either M18L or M18S to excitatory neuronal cell cultures
from the hippocampus of M18 knockouts succeeded to a
similar extent in rescuing basal synaptic activity [39].
However, M18S appeared to support high frequency
stimulation more efficiently than the long variant, suggest-
ing different roles in short-term plasticity. Altogether,
these findings indicate that the functions of M18 splice
variants may not be interchangeable, and the multiplicity
of activities attributed to M18 may represent a composite
of M18L + S.
It has been reported that de novo mutations affecting
STXBP1 gene can cause Ohtahara syndrome in humans
[40–45], a devastating neurological disease characterized
by early onset of epileptic seizures and a profound intel-
lectual disability. Most STXBP1 mutations associated with
Ohtahara syndrome impair M18–syntaxin-1 interaction
(and thereby proper SNARE assembly), compromising
cellular availability of functional M18 (haploinsufficiency)
[41, 43]. Conversely, other mutations are predicted to
confer aberrant alternative splicing of M18 RNA [44]. In
addition, some STXBP1 de novo mutations were associ-
ated with similar mental retardation without epileptic
seizures [42].
In the context of aging, two previous studies addressed
alterations in M18 protein levels in Alzheimer’s disease
postmortem brain. In the first, M18 immunodensity was
lower in two cortical areas in n = 32 Alzheimer’s disease
cases, although after synaptophysin normalization, the
authors concluded that productive synapses in Alzheimer’s
disease brains might be enriched in M18 [46]. A later
proteomic study [47] found increased M18 levels in cell
membrane extractions from cortical samples of n = 5
Alzheimer’s disease cases. These two studies did not
examine the correlation of M18 with cognitive out-
comes, or with the likelihood of dementia; nor were
potential differences in M18 splice variants assessed. In
addition, the small sample sizes limited the possibility
of investigating possible effects of stage of illness, or
potential confounders.
Altogether, clinical and preclinical data demonstrated
that M18 is essential for neurosecretion, subtle alter-
ations have a dramatic impact on normal synaptic func-
tion and cognition in humans and rodents, and could
represent an early sign of synaptic pathology and cogni-
tive impairment. For the present study we hypothesized
that cortical downregulation of M18 long and/or short
(M18L/S) splice variants could contribute to poorer
cognitive performance and increased likelihood of
dementia in old age. Due to the scarce data on specific
functions of M18 isoforms, we first performed func-
tional and anatomical characterization experiments that
evidenced the complementary, rather than overlapping
roles of M18L and M18S. Using tissue samples from
the community-based Memory and Aging Project (MAP)
[7], cortical expression of M18 variants was quantified in a
large sample of MAP participants with and without clinical
dementia, representing the range of cognitive impairment
in an elderly, aging population. The potential effects of
Alzheimer’s disease pathology on M18 levels were further
modeled using APP23 transgenic mice, which overexpress
a pathogenic variant of the human amyloid precursor
protein (APP) [48].
Results
Biochemical and anatomical evidence indicates different
roles of M18 splice variants
We first used immunoprecipitation (IP) followed by
either sodium dodecyl sulfate (SDS) or blue native (BN)
polyacrylamide gel electrophoresis (PAGE) to investigate
functional binding affinities of M18 isoforms for the
SNARE complex. As expected from their target immuno-
genic sequences (Fig. 1a), and also from previous data
[36], variant-specific antibodies selectively immunopreci-
pitated M18L or M18S without cross-reacting, confirmed
by immunoblot analyses (Fig. 1b). Surprisingly, anti-M18S
IP products were 7–12 fold enriched in SNARE proteins
(i.e. syntaxin-1, SNAP-25 and VAMP), compared to those
of anti-M18L (Fig. 1b). This was not due to a lower affinity
(See figure on previous page.)
Fig. 1 Biochemical characterization of M18 splice variants. a Alignment of M18L/S C-terminal amino acid (aa) sequences. Mismatching residues
are in red. Amino acids highlighted (in yellow) represent the immunogenic sequences used for production of variant-specific antibodies. Omitted
M18L/S N-terminal sequences are 100 % identical. b–c Immunoprecipitation (IP) of M18L/S with variant specific antibodies (and anti-mouse IgG
as a negative control) using human brain homogenates. NCI control subjects (n = 3) were tested with similar results. IP products, along with input
samples and negative controls (IgG), were resolved by (b) standard SDS- or (c) BN-PAGE, followed by either silver staining (Silver) or immunoblotting (IB)
with specific antibodies against M18 variants, syntaxin-1 (STX1), SNAP-25 (S25), or VAMP. c M18S antibody recognized two bands at ~150 and ~70 kDa,
putatively corresponding to a SNARE-M18 heterotetramer (pointed with a red arrowhead) and the monomeric form, respectively. d, f Schematic illustration
depicting the sequential extraction of (d) synaptosomes and (f) lipid rafts from human cortical homogenates. g, relative centrifugal forces; IF, interface; P,
pellet; S, supernatant. e Equivolumetric amounts of fractions obtained in (d) were resolved by SDS-PAGE and immunoblotted using antibodies targeting
M18L/S, STX1, S25, VAMP, and markers for synaptic vesicles (synaptophysin [SYP]), nuclei (FosB), nuclei + cytosol (NeuN), and myelin fragments (myelin basic
protein [MBP]). Note that MBP strongly labels P1, as heavy myelin fragments precipitate along with cell debris. g Equivolumetric amounts of fractions
obtained in (f) were resolved by SDS-PAGE and immunoblotted using the antibodies above. α-Synuclein (α-syn) antibody was additionally used, showing
similar distribution across fractions as previously reported [66]. e, g IF1 and S4 fractions were framed in a red, dashed box to highlight synaptosome and
lipid raft-enriched proteins, respectively. b–g Masses (in kDa) of prestained markers are indicated on the left side of immunoblots
Ramos-Miguel et al. Molecular Neurodegeneration  (2015) 10:65 Page 4 of 18
of the antibody for M18L, since comparable amounts of
both isoforms were observed in silver stained gels (Fig. 1b).
Rather, M18L displayed (under current assay conditions) a
poorer ability to bind syntaxin-1. Accordingly, M18S
formed a stable ~150-kDa complex with SNARE proteins,
which was barely detected in M18L co-IP products, as re-
vealed by BN-PAGE (Fig. 1c).
Substantial differences in the subcellular localization of
M18 variants were also observed (Fig. 1d–g). While M18L
was apparently restricted to the synaptosomal fraction
(IF1), M18S showed the expected wide distribution across
cytosolic (S2) and synaptosomal compartments (Fig. 1e).
Furthermore, M18L was almost exclusively found within
the Triton X-100 (TritonX)-insoluble, SDS-soluble protein
fraction (S4), matching lipid raft microdomains, while
M18S was present in water- and detergent-soluble subcel-
lular compartments (Fig. 1g).
Immunohistochemical analyses of rat brain revealed a
differential distribution of M18 variants, particularly in
the hippocampus (Fig. 2a). M18L was highly abundant
in the pyramidal cell layer of the Ammon's horn (CA)
regions, as well as in the dentate gyrus granule cell layer.
In marked contrast, M18S showed greatest immunostain-
ing in pyramidal cell-flanking strata (with particularly
strong labeling of the mossy fibers), but was barely present
within the pyramidal layer. In cortical regions, M18L accu-
mulated in neuronal perisomatic areas, whereas M18S
showed the punctate staining of neuropil typically observed
for presynaptic proteins (Fig. 2a). Despite their apparently
distinct patterns of distribution (best characterized in CA3),
confocal imaging showed some degree of overlap between
splice variants in areas such as the granule cell layer
(Fig. 2b). Of note, colocalization of M18 isoforms also over-
lapped with syntaxin-1. Similar results were observed in
human hippocampus (Additional file 1: Figure S1A). In
NeuN co-stained sections, preferential perisomatic accu-
mulation of M18L was highlighted, and additional evidence
of the cytosolic localization of M18S (but not M18L or
syntaxin-1) obtained (Fig. 2c–d).
Triple co-immunolabeling with antibodies against M18L,
vesicle GABA (VGAT) and glutamate (VGLUT1) trans-
porters showed a high degree of M18L localization within
the inhibitory (VGAT-positive) synapses, with little (or
possibly no) presence at excitatory (VGLUT1-positive)
terminals, in both cortex and hippocampus (Fig. 2e–g). In
contrast, overlap of M18S was greater with VGLUT1 than
with VGAT (Fig. 3h–j), although this could be explained by
the relative abundance of glutamatergic over GABAergic
terminals. This difference was most remarkable in CA3,
where a complete segregation of M18L and M18S
with respectively, VGAT or VGLUT1 positive termi-
nals was observed (Fig. 2f, i). In human hippocam-
pus, similar distributions were seen (Additional file
1: Figure S1B–C).
Characteristics of MAP participants and potential
confounds
Demographic, cognitive and pathological variables of MAP
participants are summarized in Table 1. No correlation was
detected between M18 splice variants and potential
confounders, including age at death, postmortem interval,
years of education and brain weight. Similarly, M18L/S
cortical immunodensity did not vary across sex, race, or
ApoE genotype. Furthermore, tobacco and/or alcohol users
did not present different M18L/S levels from those without
these histories.
Similar numbers of clinically diagnosed MAP partici-
pants with no (NCI) or mild (MCI) cognitive impairment,
and dementia were observed (Table 1). As expected, com-
mon Alzheimer’s disease pathology was largely abundant
in dementia cases, compared to NCI and MCI participants
(Fig. 3a), although some degree of variability was present
in all clinically diagnosed groups, as documented previ-
ously in larger epidemiologic studies [5, 7]. Similarly,
clinical diagnoses showed substantial, but not complete,
overlap with CERAD and Braak rating scales (Fig. 3b).
Association of cortical M18L with cognitive function and
dementia
We investigated possible alterations in the amounts of
M18 splice variants, and their potential association
with cognitive function, in samples from the dorsolat-
eral prefrontal cortex (DLPFC) of MAP participants
(n = 308). Initial inspection of quantitative immuno-
blotting datasets (normalized by β-actin content) revealed
large variability in M18L immunodensities among MAP
participants (interquartile range = 7–185 %), compared to
that of M18S (86–122 %) or β-actin (85–117 %). The
immunodensities of the M18 variants showed a non-linear
association (Additional file 1: Figure S2A, Spearman
rho = 0.53), best fitted by a semi-log curve (r = 0.56,
p < 0.001). Due to the large number of values proximate
to zero (see Additional file 1: Figure S2), and consequent
skewness (skew = 1.712), the distribution of M18L values
did not pass the Kolmogorov-Smirnov normality test. To
construct linear models, we log-transformed M18L values,
and then standardized (by subtracting the mean and
dividing by the standard deviation) both variant datasets.
Data transformations symmetrized the distribution of
M18L values and rendered linear associations between the
variants (r = 0.51, p < 0.001).
We initially conducted regression models (controlling for
demographics) to address basic associations between M18
variants, Alzheimer’s disease pathology and global cognitive
function. Lower cortical immunodensity of M18L, but not
M18S, was associated with the severity of Alzheimer’s
disease pathology, and lower cognitive scores (Fig. 4a).
Importantly, for those participants above the 90th percent-
ile of M18L the effect of higher levels of Alzheimer’s disease
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pathology on cognition was not statistically significant,
although the number of cases with high pathology was
limited, preventing definitive conclusions (Fig. 4b). In con-
trast, in subjects with M18L score below the 10th percent-
ile, cognitive function was highly sensitive to Alzheimer’s
disease pathology. While these observations suggested an
interaction between Alzheimer’s disease pathology and
M18L cortical levels, the inclusion of a statistical interaction
term in the full sample analysis did not render significance.
Decay curves for pathology-cognition associations were
similar across M18S-ranked MAP participants (Fig. 4b).
Based on prior work showing that select presynaptic
proteins were related to cognition in a relatively independ-
ent manner [13], we next generated linear regression
models to evaluate the impact of M18L on cognitive func-
tion, accounting for age-related neuropathology. In these
analyses, each of the common age-related neuropathologies
was associated to a variable degree with global and/or
Fig. 2 Immunohistochemical characterization of M18 splice variants in rat brain. (a) Photomicrographs showing M18L (upper panels) and M18S (bottom
panels) immunostaining with variant specific antibodies at various magnifications. Hippocampus and CA3 are magnified captions from the framed areas
at immediate left-side images. (b–j) Confocal images and analyses from triple co-immunolabeled sections with the antibodies indicated at the top-left
corners. Colors were arbitrarily assigned to maximize overlap visualization. (e–j) Rat brain sections were co-immunolabeled with antibodies against vesicular
GABA (VGAT) and glutamate (VGLUT1) transporters, along with (e–f) anti-M18L or (h–i) anti-M18S, and representative images from (e and h) cortical and
(f and i) hippocampal CA3 are shown. In every 6-panel composite: left and middle panels correspond to single-labeled or merged-channel images; right
panels are ImageJ-generated bitmaps resulting from colocalization analyses, in which pixels mirror the intensity of colocalization (in white) between VGAT
(top) or VGLUT1 (bottom) and the corresponding M18 splice variant. (g and j) Quantitative colocalization analyses of (G) M18L or (J) M18S with
each of the vesicular transporters (VGAT and VGLUT1) Bars represent mean ± standard error of n = 4 rats. *p < 0.05, **p < 0.01, and ***p < 0.001 (paired
t-test). Abbreviations: DG, dentate gyrus; hil, hilus; Hipp, hippocampus sg; stratum granulosum (i.e. granule cell layer); sm/l, stratum moleculare/lacunosum;
so, stratum oriens; sp, stratum pyramidale (i.e. pyralmidal cell layer); sr, stratum radiatum (in CA3 also contains stratum lucidum. Scale bars: a, 200 (CA3) or
20 (cortex) μm; b, 30 μm; c, 50 (left) or 10 (right) μm; d, 30 (left) or 10 (right) μm; e and h, 10 μm; f and i, 25 μm
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domain-specific cognitive functions (Table 2, Model 1).
Alzheimer’s disease pathology, cerebral macroinfarcts, hip-
pocampal sclerosis, arteriolosclerosis, and atherosclerosis
were all associated with poorer cognitive abilities. Lewy
bodies and microinfarcts were not, in this subset of
MAP participants. Overall, greater M18L cortical
immunodensity was associated with better cognitive
abilities (Model 2). Cortical amounts of M18L ex-
plained an additional 1.7 % of the variance in global
cognition, relatively independent of any neuropathol-
ogy. Of note, the frontal cortical M18L contribution
was significant for episodic, semantic and working
memory, but not for perceptual speed or visuospatial
skills. Variations in M18S immunodensities were not
related to global cognition or any of its domains
(Model 3); when including both M18L and M18S
(Model 4) only the M18L effect remained significant.
In a final model (not shown), we analyzed the possible
interaction between Alzheimer’s disease pathology and
M18L cortical density by adding a statistical inter-
action term to the model. No significant effect was de-
tected for this interaction term.
Grouping MAP participants by clinical diagnosis
revealed that dementia cases had lower M18L cortical
immunodensity (−51 %, p < 0.001) than those with no
dementia (Fig. 4c–d). Differences were also noted when
subjects were graded using either NIA/Reagan or Braak,
with lower M18L levels (−77 % and−64 %, respectively)
in participants with high probability of Alzheimer’s
disease (i.e. subjects falling into NIA/Reagan group 1
and/or Braak stage V–VI) (Additional file 1: Figure S2B).
Minimal differences for M18S were observed across clinical
diagnoses or postmortem rankings. In further multiple
logistic regression analyses we aimed to evaluate the signifi-
cance of M18L cortical downregulation to the likelihood of
clinical dementia (Table 3). As expected, each unit of
Alzheimer’s disease pathology, cerebrovascular disease
(excluding microinfarcts), Lewy bodies and hippocampal
sclerosis increased the odds of dementia (Table 3, Model 1).
Each unit of M18L, however, was associated with lower
odds of dementia, without altering the effects of neuropa-
thologies (Model 2). The probability of dementia was not
related to M18S cortical levels (Model 3), which in turn did
not modify M18L effects (Model 4).
Fig. 3 Burden of Alzheimer’s disease pathology in MAP participants and relation to clinical diagnoses. a Composite Alzheimer’s disease (AD) pathology
values were estimated for each participant and plotted by clinical diagnosis criteria into no- (NCI, n = 90), or mild-cognitive impairment (MCI, n = 86), or
dementia (DEM, n = 132). Whiskers represent 10th and 90th percentiles and boxes enclose interquartile ranges crossed by the median of Alzheimer’s
disease pathology scores within groups. As expected, Kruskal-Wallis test detected differences on the accumulated Alzheimer’s disease pathology across
clinical diagnoses (KW-statistic = 57.0, p < 0.001; Mean rank differences: NCI vs MCI = 30.7; NCI vs DEM = 88.7; MCI vs DEM = 58.0). ns, not
significant, ***p < 0.001, Kruskal-Wallis followed by Dunn’s multiple comparison test. b Bubble plot illustrating the distribution of MAP participants across
clinically diagnosed (NCI/MCI/DEM) and neuropathologically graded [by NIA/Reagan, CERAD (Consortium to Establish a Registry for Alzheimer’s Disease),
and Braak scales] groups
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APP23 mice do not show alterations in M18L/S cortical
amounts
We used APP23 transgenic mice to examine the associ-
ation between M18L and a common Alzheimer’s disease
pathology (i.e. amyloid plaques). These animals develop
an Alzheimer’s disease-like syndrome via expression of a
mutant APP that causes abnormal, age-dependent extra-
synaptic amyloid-β accumulation [48]. M18L/S cortical
immunodensities were compared between adult (12-
month old) and aged (22-month old) APP23 mice, and
age-matched wild type (WT) littermates. Although overt
synaptic damage is reported in APP23 mice [48], cortical
levels of M18L/S were not significantly different from
those in WT controls, at either age (Fig. 5). However,
M18L was slightly reduced in aged rats regardless of
genotype (−13 to −16 %, p > 0.05), while APP23 mice
tended to display lower M18S cortical immunodensities
regardless of age (−21 to−22 %, p > 0.05). These marginal
effects were considerably smaller than the M18L loss
(−64 %) observed in the DLPFC of MAP participants
graded according to Braak’s V–VI stages.
Discussion
In the present study, variations in frontal cortical
M18 levels were associated with cognitive function
and the likelihood of dementia in the elderly, beyond
the effects of common age-related neuropathologies.
Specific loss of M18L (but not M18S), which was
found preferentially at GABAergic presynaptic










Female, no. (%) 194 (63 %) 64 (71 %) 48 (56 %) 82 (62 %)
Age at death, years 88.8 ± 6.0 86.8 ± 6.3 88.1 ± 6.4 90.7 ± 5.0
Education, years 14.4 ± 2.8 14.0 ± 2.4 14.7 ± 2.5 14.5 ± 3.2
Race, no. W:AA:NA 300:7:1 86:4:0 84:1:1 130:2:0
APOE ε4 allele, no. (%) 84 (27 %) 15 (17 %) 22 (26 %) 47 (36 %)
PMI, hours 7.2 ± 4.8 6.9 ± 4.4 8.1 ± 5.5 6.7 ± 4.6
Cognitive function proximate to death
Global cognition score −0.85 ± 1.09 0.16 ± 0.41 −0.43 ± 0.45 −1.83 ± 0.88
Episodic memory −0.84 ± 1.19 0.34 ± 0.48 −0.55 ± 0.70 −1.84 ± 0.90
Semantic memory −0.70 ± 1.23 0.12 ± 0.56 −0.19 ± 0.53 −1.61 ± 1.31
Working memory −0.66 ± 1.14 0.16 ± 0.77 −0.29 ± 0.79 −1.50 ± 1.01
Perceptual speed −1.13 ± 1.13 −0.28 ± 0.85 −0.70 ± 0.88 −2.02 ± 0.77
Visuospatial ability −0.63 ± 1.23 0.12 ± 0.62 −0.16 ± 0.78 −1.49 ± 1.29
MMSE 21.3 ± 8.8 28.1 ± 1.8 25.7 ± 3.8 13.6 ± 8.2
Pathological
NIA/Reagan scale, no. in 1:2:3:4b 49:135:120:4 4:25:59:2 4:44:36:2 41:66:25:0
CERAD scale, no. in 1:2:3:4c 95:99:40:74 13:21:19:37 19:31:13:23 63:47:8:14
Braak stage, no. in 0:I:II:III: 4:20:33:91: 2:14:16:33: 2:2:14:28: 0:4:3:30:
IV:V:VI 88: 67:5 21:4:0 30:10:0 37:53:5
Global AD pathology 0.69 ± 0.62 0.38 ± 0.39 0.60 ± 0.57 0.97 ± 0.66
Macroinfarcts, no. (%) 108 (35 %) 20 (22 %) 29 (34 %) 59 (45 %)
Microinfarcts, no. (%) 71 (23 %) 20 (22 %) 14 (16 %) 37 (28 %)
Lewy body disease, no. (%) 27 (9 %) 2 (2 %) 4 (5 %) 21 (16 %)
Hippocampal sclerosis, no. (%) 26 (8 %) 1 (1 %) 5 (6 %) 20 (15 %)
Abbreviations: AA Afro-American, AD, Alzheimer’s disease, BL baseline, CERAD Consortium to establish a registry for AD, MCI mild cognitive impairment, MMSE mini
mental state examination, NA Native-American, NCI no cognitive impairment, NIA National Institute on Aging, no number of subjects, PMI postmortem interval, SD
standard deviation, W White
aValues are mean ± SD unless noted otherwise
bNIA/Reagan scale: high (1), intermediate (2), low (3), or no (4) likelihood of AD, according to neuritic plaques and tangles
cCERAD scale: definite (1), possible (2), probable (3), or no (4) AD, according to neuritic plaques
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Fig. 4 (See legend on next page.)
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terminals, may initiate synaptic dysfunction and con-
sequent synaptic pathology.
We first characterized biochemical, cellular and
anatomical aspects of M18 splice variants. Compared to
M18S, M18L showed minimal binding affinity for
syntaxin-1 (and hence for the SNARE complex) in two
functional assays, co-IP and BN-PAGE. A previous study
showed similar, but less pronounced, variant-specific
binding affinities to syntaxin-1 [32]. Furthermore, in a
yeast two-hybrid setting, depletion of any segment of the
(See figure on previous page.)
Fig. 4 Associations of M18 splice variants with Alzheimer’s disease pathology, global cognition and clinical dementia. a Contour plots illustrating MAP
participants’ (n = 308) global cognition (z-score) as a function of M18L or M18S DLPFC immunodensities, and Alzheimer’s disease (AD) pathology. Only
AD pathology ×M18L (r =−0.251, p < 0.001), AD pathology × global cognition (r =−0.545, p < 0.001), and M18L × global cognition (r = 0.373, p < 0.001)
were significantly correlated. b Regression analyses predicting global cognition as a function of AD pathology in groups of MAP participants having M18L
or M18S immunodensities above 90th (green), between 10th and 90th (blue), or below 10th percentile (red). Lines represent best-fit curves
and 95 % confident intervals. For M18L, significant correlations between AD pathology and global cognitive function were observed for participants among
the lowest (r =−0.735, p < 0.001, n = 31) and intermediate (r =−0.512, p < 0.001, n = 243), but not the highest (r =−0.399, p = 0.074, n = 31), M18L groups. For
M18S, statistically significant correlations were seen in all three M18S ranked groups: low (r =−0.460, p = 0.036, n = 31), intermediate (r =−0.559, p < 0.001,
n = 245) and high (r =−0.509, p = 0.021, n = 29). cWhiskers represent 10th and 90th percentiles of M18L or M18S values, with boxed interquartile ranges
crossed by the median, in participants with no- (NCI, n = 90), or mild-cognitive impairment (MCI, n = 86), or with dementia (DEM, n = 132). One-way ANOVA
detected a significant effect only for M18L (F(2305) = 8.77, p < 0.001). *p < 0.05 and ***p < 0.001, ANOVA followed by Bonferroni’s test. d Representative
immunoblots of M18L/S and β-actin, with various participants and standard (std) samples. Masses are indicated in kDa
Table 2 Linear regression modelsa predicting global or single-domain cognitive function
Model no.
and terms
Global cognition Episodic memory Semantic memory Working memory Perceptual speed Visuospatial ability
(n = 302) (n = 302) (n = 296) (n = 301) (n = 293) (n = 289)
r2 or βb p-value r2 or β p-value r2 or β p-value r2 or β p-value r2 or β p-value r2 or β p-value
Model 1 0.328 0.394 0.208 0.174 0.189 0.121
AD pathology −0.872 <0.001 −1.091 <0.001 −0.713 <0.001 −0.634 <0.001 −0.477 <0.001 −0.362 0.014
Macroinfarcts −0.283 0.016 −0.253 0.039 −0.366 0.011 −0.470 0.001 −0.052 0.681 −0.065 0.657
Lewy bodies −0.184 0.193 −0.111 0.452 −0.027 0.875 −0.102 0.533 −0.027 0.857 −0.112 0.518
Hipp sclerosis −0.660 0.001 −1.034 <0.001 −0.662 0.005 −0.143 0.529 −0.687 0.001 −0.315 0.198
Model 2 0.345 0.406 0.226 0.193 0.193 0.123
AD pathology −0.793 <0.001 −1.018 <0.001 −0.628 <0.001 −0.549 <0.001 −0.434 0.001 −0.323 0.032
Macroinfarcts −0.269 0.021 −0.240 0.048 −0.347 0.014 −0.455 0.001 −0.043 0.731 −0.058 0.693
Lewy bodies −0.141 0.314 −0.071 0.630 0.021 0.900 −0.055 0.735 −0.004 0.981 −0.088 0.611
Hipp sclerosis −0.658 0.001 −1.032 <0.001 −0.665 0.005 −0.141 0.530 −0.686 0.001 −0.317 0.196
M18Lc 0.0010 0.003 0.0009 0.009 0.0012 0.006 0.0011 0.006 0.0005 0.141 0.0005 0.226
Model 3 0.328 0.392 0.209 0.177 0.188 0.120
AD pathology −0.865 <0.001 −1.090 <0.001 −0.707 <0.001 −0.624 <0.001 −0.470 <0.001 −0.357 0.016
Macroinfarcts −0.290 0.014 −0.255 0.038 −0.372 0.010 −0.483 <0.001 −0.057 0.650 −0.071 0.629
Lewy bodies −0.175 0.217 −0.108 0.464 −0.011 0.947 −0.086 0.598 −0.018 0.907 −0.100 0.566
Hipp sclerosis −0.670 0.001 −1.037 <0.001 −0.676 0.005 −0.160 0.480 −0.696 0.001 −0.325 0.184
M18Sc 0.0016 0.331 0.0004 0.794 0.0024 0.247 0.0027 0.150 0.0015 0.389 0.0018 0.383
Model 4 0.343 0.405 0.224 0.191 0.190 0.120
AD pathology −0.793 0.001 −1.014 <0.001 −0.629 <0.001 −0.551 <0.001 −0.436 0.001 −0.626 0.021
Macroinfarcts −0.267 0.022 −0.232 0.057 −0.348 0.014 −0.460 0.001 −0.047 0.714 −0.062 0.673
Lewy bodies −0.141 0.313 −0.074 0.614 0.022 0.896 −0.053 0.745 −0.002 0.990 −0.085 0.625
Hipp sclerosis −0.657 0.001 −1.023 <0.001 −0.667 0.005 −0.146 0.515 −0.690 0.001 −0.321 0.189
M18Lc 0.0010 0.006 0.0011 0.006 0.0011 0.013 0.0010 0.017 0.0005 0.217 0.0004 0.343
M18Sc −0.0003 0.877 −0.0015 0.419 0.0003 0.890 0.0009 0.669 0.0006 0.741 0.0010 0.658
Abbreviations: AD Alzheimer’s disease Hipp, hippocampal; M18L/S, Munc18-1 long/short splice variant
aAll models included terms (not shown) for age, sex, education, microinfarcts, arteriolosclerosis, and atherosclerosis
bValues are whole model adjusted r-squared, or individual β-coefficients for each term
cStandardized M18L/S values (z-scores) were used
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M18S (M18L was not reported) amino acid sequence
(including the 25 C-terminal residues) completely
abolished M18-syntaxin-1 association [49]. It is possible
that the present assay conditions (e.g. absence of Ca2+)
may induce a SNARE conformation that favors M18S
relative to M18L binding in vitro. Since binding to
syntaxin-1 is the major mechanism by which M18 exerts
its functions [23, 28, 29], future studies should address
this apparent difference in M18 variants in more detail.
Given its globular, hydrophilic nature, M18 attachment to
cell membranes is thought to occur through syntaxin-1
interaction [50]. Despite the lower affinity for syntaxin-1,
M18L seemed confined to the highly hydrophobic, lipid
raft-enriched fraction. While the role of these cholesterol-
enriched microdomains in regulated exocytosis is unclear,
some studies proposed that specific pools of target SNARE
proteins may concentrate at lipid rafts, which in turn could
discriminate between different kinds of neurotransmitter-
containing vesicles [51]. Of note, the M18L C-terminal
sequence does not display specific motifs for palmitoylation
(cysteine enriched sequences), myristoylation (typically
occurring at a N-terminal glycine), or prenylation (typically
in a C-terminal cysteine), major post-translational modifica-
tions determining membrane localization for globular
proteins. Possible explanations for M18L localization at
lipid rafts could include a preferential M18L–syntaxin-1
interaction in the biochemical environment of these mem-
brane microdomains, or alternatively, M18L may display
greater affinity for another raft-attached protein. Munc18-
interacting proteins (Mint1/2) may be key partners in this
process, as they bear two membrane-attaching PDZ
domains in addition to a M18-binding sequence [52].
Remarkably, Mint1/2 can regulate M18-syntaxin-1 inter-
action and were found also altered in Alzheimer's diseased
postmortem brains [46]. Additionally, the presence of a
putative phosphoserine site for Ca2+-calmodulin kinase II
(CaMKII) activity in the C-terminal tail of M18L, but not
M18S, may indicate a differential regulatory mechanism for
the M18 variants [39]. This CaMKII activity was presumed
to be responsible for the enhanced depression of synchron-
ous vesicle release in M18 null pyramidal neurons rescued
with M18L, compared to those carrying M18S only.
Immunohistochemical assays were consistent with tissue
fractionation experiments. In contrast to the wide distribu-
tion of M18S across subcellular compartments, M18L was
restricted to nerve endings and enriched in perisomatic
areas. The M18S subcellular and histological distribution
was similar to that previously reported for M18 [32, 53],
and no cell-type specificity was presumed. The distribution
of M18L was consistent with the localization expected for
GABAergic presynaptic proteins [54]. Indeed, M18L closely
matched VGAT distribution in all brain areas analyzed,
especially in the hippocampus, where it was abundantly
expressed in the perisomatic area of pyramidal cells. Inter-
estingly, a previous in situ hybridization showed greatest
expression of M18L in cells within the granule and pyram-
idal layers of mouse hippocampus [35]. Combined, these
experiments indicate that M18L protein is mainly present
in the presynaptic terminals of GABAergic interneurons
within these hippocampal layers, although we cannot
exclude some residual M18L expression in glutamatergic or
other neuromodulatory terminals. This finding suggests a
qualitative difference between the neurosecretory mecha-
nisms of excitatory and inhibitory neurons. Several epileptic
syndromes have been associated with firing abnormalities
of dentate gyrus granule cells, likely due to an inappropriate
inhibitory tone [55, 56]. This model is consistent with
the mutations in M18 related to Ohtahara syndrome
[41, 45], a disease accompanied by seizures and severe
intellectual disability.
We found marked reductions of M18L, but not M18S,
in DLPFC of MAP participants displaying clinical
Table 3 Logistic regression modelsa predicting likelihood of clinical dementia per unit of term
Model terms Model 1 Model 2 Model 3 Model 4
Odds
ratio
95 % CI p-value Odds
ratio
95 % CI p-value Odds
ratio
95 % CI p-value Odds
ratio
95 % CI p-value
AD pathology 3.15 1.80–5.73 <0.001 2.84 1.60–5.22 <0.001 3.16 1.81–5.75 <0.001 2.83 1.59–5.21 <0.001
Macroinfarcts 2.16 1.20–3.94 0.010 2.06 1.14–3.79 0.017 2.20 1.22–4.02 0.009 2.05 1.13–3.78 0.018
Microinfarcts 0.73 0.39–1.36 0.326 0.77 0.41–1.43 0.412 0.75 0.40–1.40 0.370 0.77 0.41–1.43 0.409
Arteriolosclerosis 1.30 0.95–1.78 0.098 1.34 0.98–1.84 0.068 1.32 0.97–1.82 0.078 1.33 0.98–1.84 0.071
Atherosclerosis 1.36 1.02–1.82 0.035 1.36 1.02–1.84 0.038 1.34 1.00–1.80 0.046 1.36 1.02–1.84 0.038
Lewy bodies 4.92 1.79–15.40 0.002 4.63 1.67–14.70 0.003 4.93 1.79–15.51 0.002 4.62 1.66–14.66 0.003
Hipp sclerosis 4.39 1.72–12.16 0.002 4.41 1.70–12.39 0.002 4.59 1.78–12.80 0.001 4.38 1.68–12.34 0.002
M18Lb 0.68 0.50–0.90 0.008 0.67 0.47–0.93 0.018
M18Sb 0.84 0.64–1.10 0.208 1.03 0.75–1.43 0.871
Abbreviations: AD Alzheimer’s disease, CI confidence interval Hipp, hippocampal, M18L/S Munc18-1 long/short splice variant
aAll models were controlled for age, sex and education
bStandardized M18L/S values (z-scores) were used
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dementia and/or a large burden of Alzheimer’s disease
pathology. Pairwise correlations between M18L levels,
the burden of Alzheimer’s disease pathology, and cogni-
tive function scores were all significant. Accordingly,
participants having high M18L cortical density displayed
greater cognitive resistance against the accumulation of
Alzheimer’s disease pathology, which may directly im-
plicate M18L in the molecular mechanisms of cogni-
tive reserve. Statistical modeling indicated that loss of
M18L contributed moderately to a higher likelihood of
dementia and to cognitive impairment. Additionally,
including synaptophysin as a covariate did not alter
the results, suggesting that loss of M18L is an early
event in synaptic pathology. The importance of main-
taining appropriate splicing balance between M18L/S
isoforms is probably best represented by the dramatic
endophenotypes observed in murine strains either
lacking or overexpressing the M18L variant [34, 35].
While specific regulatory splicing mechanisms of the
STXBP1 transcript are unclear, other splicing deficits
have been associated with aging related neuropathol-
ogies and dementia [57].
The predominant expression of M18L in GABAergic
terminals suggests that synaptic deficits may be initi-
ated in inhibitory, rather than excitatory synapses. This
could be related to the surprising relative upregulation
of glutamatergic terminals observed in MCI [58]. Indeed,
there is compelling evidence involving GABAergic system
in early stages of dementia [59, 60]. By contrast, previous
observations in transgenic mouse models suggested that
cholinergic and glutamatergic terminals may collapse first
as a result of APP-mediated synaptic damage [61]. In the
present study, APP23 mice did not display reduced levels
of M18L/S, which agrees with previous findings [46].
Thus, cortical loss of M18L may be an independent event
from amyloid-β accumulation, and perhaps other com-
mon age-related neuropathologies, and could represent a
distinct contribution to cognitive impairment, possibly
through erosion of cognitive reserve.
Conclusions
The present study identified the M18L isoform as a rela-
tively specific component of the GABAergic presynaptic
machinery. In contrast to the alternatively spliced M18S,
which is highly abundant and ubiquitously expressed in
inhibitory and excitatory neurons, M18L appears restricted
to lipid raft microdomains within the presynaptic compart-
ment, and may have a function independent from its inter-
action with syntaxin-1. Importantly, M18L, but not M18S,
is associated with cognitive function in the elderly, and may
contribute to the mechanisms of cognitive reserve that pro-
tect against dementia related to age-associated pathologies.
Methods
Participants, cognitive evaluations and neuropathological
assessments
MAP recruits volunteers without known dementia,
living in Chicago (IL, USA) [7]. Since 1997, this study
enrolled over 1750 community-dwelling participants.
At enrollment, all participants signed an informed
consent and an Anatomic Gift Act for organ donation upon
death. All protocols were approved by the Institutional
Review Board of Rush University Medical Center. The
overall follow-up rate is 95 % and the autopsy rate exceeds
80 %. Samples obtained in a consecutive series of autopsies
Fig. 5 M18 splice variants are not altered in APP23 mice. a
Immunodensities of M18L/S splice variants were quantified by
Western blotting in brain homogenates (frontal cortex) from
adult (12-month-old; T12) and aged (22-month-old; T22) wild
type (WT) and APP23 transgenic mice. Columns are immunodensity
mean values ± standard error (normalized by β-actin) of n = 6 mice
per group, and represented in percentage to control (T12–WT) animals.
Two-way ANOVA only detected a significant effect for genotype
(but not age) on M18S (F(1,20) = 4.51, p = 0.0462), and a borderline
age (but not genotype) effect on M18L (F(1,20) = 3.44, p = 0.0784), without
specific between-group differences in the following Dunnett’s post hoc
tests. b Representative immunoblots of M18L, M18S and β-actin, with
one sample per group. Masses (in kDa) of proximal prestained markers
are indicated on the left side of immunoblots
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of n = 308 participants were included in the present study.
A summary of demographic, cognitive and pathological
characteristics is listed in Table 1.
Methodological approaches to systematic cognitive,
clinical and neuropathological evaluations were extensively
reported [7, 62]. Annual cognitive evaluations comprised a
battery of 21 standard tests, 19 of which are used to
summarize one of the following domains: episodic memory,
semantic memory, working memory, perceptual speed or
visuospatial ability. For the present work, last valid cogni-
tive tests were used in all analyses. The 19 tests could also
be combined into a single variable, based on an average
z-score to summarize global cognitive function nearest
to death [7, 63]. The final clinical diagnoses of dementia
followed the National Institute of Neurological and Com-
municative Disorders and Stroke and the Alzheimer’s
Disease and Related Disorders Association criteria [64], and
were made by a board-certified neurologist blind to all
pathological data.
Neuropathological examinations documented Alzheimer’s
disease-related pathology (neuritic and diffuse plaques, and
neurofibrillary tangles), vascular diseases (macroscopic and
microscopic infarcts, arteriolosclerosis and atheroscler-
osis), Lewy bodies, and hippocampal sclerosis [7, 62]. A
board-certified neuropathologist made all diagnoses
blind to all clinical data. A composite measure of global
Alzheimer’s disease pathology was created using a stan-
dardized average of neuritic and diffuse plaques and
neurofibrillary tangles [62]. The burden of Alzheimer’s
disease pathology was also categorized using Braak,
CERAD and NIA/Reagan scales.
Animals
Approval from the UBC’s Animal Care Committee was
obtained prior to experiments involving laboratory
animals. Adult Sprague–Dawley rats were supplied by
Charles-River (Montreal, QC, Canada). Novartis Pharma
(Basel, Switzerland) provided APP23 transgenic mice, over-
expressing a variant of human APP carrying the ‘Swedish
double mutation’ KM670/671NL [48]. Pentobarbital-
anaesthetized adult rats, as well as 12- or 22-month old
APP23 mice and wild-type (WT) littermates, were killed
by decapitation. Hemispheres were separated, and used
for electrophoretic or immunohistochemical assays.
Purification of synaptosomes
Cortical synaptosomes were obtained following standard
procedures (see cartoon in Fig. 1d), similar to those
originally developed by Grey and Whittaker in the
1960’s [65]. All sucrose solutions described below were
HEPES-buffered (4 mM, pH 7.4), supplemented with
1 % of a protease inhibitor cocktail (Sigma, St. Louis,
MO, USA), and pre-chilled at 4 °C. Approximately 1 g
of human inferior temporal cortex was homogenized in
10 ml of 0.32 M sucrose buffer, using a motorized 20-ml
Potter-Elvehjem tissue grinder, with a clearance of 0.13–
0.18 mm between the Teflon pestle and the glass chamber.
The following centrifugal separations were all per-
formed at 4 °C in an Avanti J-30I high performance
centrifuge (Beckman Coulter, Fullerton, CA, USA),
equipped with a JA-30.50 fixed angle rotor. Tissue
debris, along with cell nuclei, were removed at 1000 ×
g for 1 min (P1). Supernatants (S1) were centrifuged at
17,000 × g for 15 min, and the resulting pellets (P2)
washed in 0.32 M sucrose and re-centrifuged. P2 fractions
were resuspended in 0.32 M sucrose and layered onto a
sucrose discontinuous gradient, with 1.2 (bottom), 0.8 M
(middle), and 0.32 M (topping) layers. After a 12-h
centrifugation at 96,000 × g, the interfaces between 0.8
and 1.2 M (IF1, containing the crude synaptosomal
fraction), and 0.32–0.8 M (IF2, mainly myelin-coated
fragments) were collected. IF1 was again overlaid on
0.32 M sucrose buffer and centrifuged at 30,000 × g
for 20 min. The resulting pellet, containing purified
synaptosomes, was resuspended in 1 ml of
homogenization buffer supplemented with 0.5 %
TritonX. In all steps, aliquots of each fraction were
separated for further SDS-PAGE and immunoblotting
analyses.
Extraction of lipid rafts
Purification of lipid raft-enriched fraction was based on
the TritonX-insoluble, SDS-soluble property of these
membrane microdomains. The present method, initially
designed for separating cytosolic from insoluble, raft-
associated α-synuclein [66], offers a simple and quick
assay to yield a fraction (S4) of TritonX-insoluble pro-
teins highly enriched in lipid rafts through sequential
centrifugation steps [67]. Figure 1f in the main text
illustrates the procedure. Briefly, ~150 mg of cortical
tissue were homogenized in 1.5 mL of ice-cold 10 mM
Tris-buffer, pH 6.8, containing 1 % of a protease inhibitor
cocktail (Sigma). Total homogenate (TH) was centrifuged
at 31,000 × g for 1 h at 4 °C. Supernatant was collected (S1),
and the pellet (P1) was resuspended in 1 ml of the same
ice-cold Tris-buffered solution supplemented with 0.5 %
TritonX. To achieve a homogenous solution, P1 was gently
sonicated (F60 Sonic Dismembrator, Fisher Scientific, Wal-
tham, MA, USA). The same centrifugation step was per-
formed and the supernatant (S2) was kept. The pellet (P2)
was again resuspended and sonicated in Tris-buffer con-
taining 2 % TritonX, and the centrifugation step was
repeated. The subsequent supernatant (S3) was separated
and the pellet (P3) homogenized as above in ice-cold
Tris-buffer containing 0.5 % SDS. P3 was incubated at
15 °C with rotation for 10 min before a final centrifuga-
tion at 31,000 × g and at 12 °C was performed for 1 h.
The supernatant (S4), enriched in lipid-raft proteins,
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was collected, and the final pellet (P4) resuspended as
above. All fractions were stored at−80 °C until resolved
by SDS-PAGE and immunoblotting.
Antibodies
A list of primary antibodies used appears in Additional
file 2: Table S1. Commercial antibodies selectively
targeting M18L and M18S variants were raised against
their respective C-terminal amino acidic sequences
(Fig. 1a), which share 100 % homology across human
and rodent orthologues. The isoform-selectivity of
these antibodies was previously reported [36], and
further characterized by co-immunoprecipitation.
Production and characterization of mouse monoclonal
antibodies against syntaxin-1, SNAP-25, VAMP and
synaptophysin was described elsewhere [68, 69]. Peroxid-
ase- and Alexa-Fluor 488/555/647-conjugated secondary
antibodies were from Jackson ImmunoResearch Laborator-
ies (West Grove, PA, USA) or Molecular Probes (Eugene,
OR, USA), respectively.
Immunoprecipitation
Target proteins were immunoprecipitated using protein G-
coated magnetic Dynabeads (Life Technologies, Carlsbad,
CA, USA), as reported [38]. In each reaction, 50 μg of
beads were incubated in phosphate-buffered saline (PBS),
supplemented with 0.1 % TritonX, and containing 0.33 μg
of anti-mouse IgG (negative control), or antibodies against
either M18L or M18S splice variants. Nonspecific binding
sites were blocked in the same buffer supplemented with
3 % bovine serum albumin (BSA). In parallel, human
cortical samples were ground homogenized in PBS contain-
ing 1 % TritonX, and 1 % of protease inhibitors (Sigma),
and solubilized for 1 h at 4 °C. Prior to IP reactions, solubi-
lized brain proteins were pre-cleared with antibody-free
beads. Antibody-conjugated magnetic beads were com-
bined with excess (2 mg) of pre-cleared brain proteins, and
incubated overnight at 4 °C. After washing, IP products
were eluted in 25 μl of 20 mM tricine, pH 2.7 to preserve
native protein structures and interactions.
Quantitative immunoblotting
Grey matter samples from the middle-frontal gyrus
(Brodmann’s area 46/9) of the DLPFC were obtained at
autopsies of MAP participants, following a standard atlas
[70]. The DLPFC was selected for its central role in
complex cognitive tasks and contribution to age-related
cognitive decline [71]. Samples (40–80 mg) were ground-
homogenized using a Teflon pestle in ice-cold PBS,
pH 7.4, and stored at−80 °C until use [13]. Prior to immu-
noassays, protein concentrations were determined by DC
assay (Bio-Rad, Hercules, CA, USA), and samples adjusted
to equal concentrations with homogenization buffer.
Quantification and characterization of M18L/S vari-
ants and β-actin in MAP cortical samples was achieved
by SDS-PAGE, using 10 % or 12 % minigels (Bio-Rad),
followed by immunoblotting, as previously reported [38].
Quantification of other presynaptic proteins was previ-
ously reported [13]. Total brain homogenates (and also
subcellular fractions or IP products) were combined
with equal volumes of 2× loading buffer (100 mM Tris,
pH 6.8, 4 % SDS, 0.2 % bromophenol blue, 20 % glycerol,
200 mM β-mercaptoethanol). All samples were boiled
for 5 min prior to electrophoretical separations. Prelim-
inary analyses determined that 10-μg protein aliquots of
total brain homogenates from DLPFC were optimal for
densitometric quantifications [36]. The standard sample
(pool of n = 132 MAP participants) was spaced-loaded in
triplicate in all gels to control for correct loading and
protein transfer to the membranes (see Fig. 4d), and also
to account for between-gel variability. For quality con-
trol, immunoblots were rejected when the coefficient of
variation (CV) of in-gel standard samples exceeded
10 %, although typical CV < 5 % values were obtained.
For the analysis of brain fractions, equivolumetric
amounts were loaded onto the SDS-gels, while 5 μl of IP
products were found optimal. All brain samples were
resolved in 10–12 % polyacrylamide minigels (Bio-Rad,
Hercules, CA, USA). After electrophoresis, proteins
were transferred to polyvinylidene difluoride (PVDF)
membranes, and subsequently blocked (1 h), and incu-
bated with primary (overnight, 4 °C; see Additional file
2: Table S1) and secondary (1 h; 1:5000) antibodies, in
TBS containing 5 % milk and 0.1 % Tween-20. Chemilu-
minescence was enhanced with commercial reagents
(Perkin Elmer, Waltham, MA, USA), and images were
digitized using a LAS-3000 Image Reader (Fujifilm,
Tokyo, Japan).
In quantitative studies, membrane stripping and reprob-
ing with anti-β-actin antibody was done for housekeeping
and data normalization purposes. Densitometric analyses of
the immunoblots were done with ImageGauge software,
version 4.22 (Fujifilm). Every gel was run with 14 brain
samples (including 11 MAP participants randomly selected,
and the triplicate standard sample), and a molecular weight
ladder (Bio-Rad). Gels containing the same subset of
samples were assessed at least twice in different days. For
quality control, a minimal between-gel Pearson’s correlation
coefficient of r = 0.80 was required for M18L/S and β-actin
immunoreactivity values. Gels not meeting this criterion
were discarded and repeated. For each sample, immunore-
activity of M18L/S (in arbitrary optical density units) was
first divided by that of β-actin within the same gel, and then
calculated as a percentage of in-gel standards. Mean value
between the two different, valid gels was used as a final es-
timate. This procedures were reported to reduce the ex-
perimental variability in studies that used immunoblotting
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as a quantitative technique for large cohorts of samples
[36, 38].
BN-PAGE
Originally developed to study mitochondrial mem-
brane complexes [72], separation of solubilized brain
proteins by BN-PAGE was recently shown suitable to
identify and quantify presynaptic complexes in human
postmortem tissue [38]. Brain samples were combined
with equal volumes of ice-cold 100 mM Bis-tris,
pH 7.0, solubilization buffer, containing 50 mM NaCl,
2 mM EDTA, 4 mM 6-aminohexanoic acid, 1 %
TritonX, and 1 % protease inhibitor cocktail, and incu-
bated for 1 h at 4 °C with gentle rotation. After centri-
fugation (16,000 × g, 30 min, 4 °C), supernatants or IP
products were combined with equal volumes of a loading
buffer (0.5 % TritonX, 0.25 % Coomassie brilliant blue G-
250, 10 % glycerol). Samples were loaded in 4–16 % gradi-
ent NativePAGE precast gels (Novex, Carlsbad, CA, USA).
Electrophoresis was run under constant voltage (150 V), at
4 °C, with pre-chilled anode (50 mM Bis-tris, pH 7.0) and
cathode (15 mM Bis-tris, 50 mM tricine, pH 7.0, 0.02 %
Coomassie dye) buffers. Before transferring proteins and
complexes to PVDF membranes, BN-gels were incubated
an ice-cold 12 mM Tris, 96 mM glycine buffer, pH 8.3,
containing 0.1 % SDS. To remove excess of Coomassie dye,
membranes were rinsed in 100 % methanol, followed by
immediate rehydration in TBS for 15 min. Following
immunoblotting procedures were as described for SDS-
PAGE. Molecular markers (NativeMARK, Novex, range
20–1240 kDa) were loaded in all gels to estimate protein
complex sizes.
Immunohistochemistry and immunofluorescence
Forty-μm floating coronal sections (−3.30 to−4.20 rela-
tive to bregma) were obtained from paraformaldehyde-
fixed rat brain hemispheres [73]. Other floating coronal
sections were from the mid-hippocampus of selected
cases with or without dementia [74]. Retrieval of the
M18L epitope required 20-min incubation at 95 °C in
20 mM Tris buffer (pH 9.0), containing 1 mM EDTA
and 0.05 % Tween-20, possibly because of the major
localization in TritonX-insoluble subcellular compart-
ments (see Results). Other antigen retrievals were done
in 20 mM citrate buffer (pH 6.0) at 80 °C for 15 min. For
procedures involving 3,3′–diaminobenzidine staining, we
used commercially available kits (Vector Labs, Burlingame,
CA, USA), with incubations as reported [75]. Images were
acquired with an Olympus BX61 microscope (Olympus,
Tokyo, Japan). Immunofluorescence assays were performed
as described [74, 76]. A series of orthogonal images were
obtained using a LSM 5 Pascal confocal microscope (Zeiss;
Jena, Germany). Co-staining of M18L/S isoforms with
VGAT and VGLUT1 was assessed to determine
presence in inhibitory or excitatory presynaptic termi-
nals, respectively. Appropriate negative controls were
included in all experiments.
Statistical analyses
In quantitative immunoblotting assays, M18L/S immu-
nodensities were first normalized to corresponding β-
actin values, and calculated as a percentage of in-gel
standards [36, 38]. Linear models were constructed with
log-transformed (M18L) and/or standardized (M18L and
M18S) values (z-scores). Data transformations did not
alter the observed differences between groups.
Multivariate analyses were performed to survey puta-
tive associations between M18 isoforms and cognitive,
pathological, neurochemical and/or putative confound-
ing variables. An additional exploratory analysis was
performed by ranking participants according to their
M18L/S cortical immunodensities and comparing
pathology-cognition decay curves across subjects with
high (above the 90th percentile) and low (below 10th
percentile) M18L/S values. Given the potential effect of
cortical M18L levels on cognitive performance, we
generated multiple linear regression models with cogni-
tive measures as outcomes and pathological and neuro-
chemical variables as predictors. Additionally, using the
same predictors, we built logistic regression models
with clinical diagnosis of dementia as the outcome.
Linear and logistic models were controlled for sex, age
and education. Differences in M18 immunodensities
between clinically diagnosed or pathologically graded
groups were assessed by ANOVA followed by Bonferroni’s
post hoc test for standardized data, or Kruskal-Wallis
followed by Dunn’s post hoc tests for non-transformed
values. Experiments involving APP23 mice were analyzed
with two-way ANOVA, with genotype and age as inde-
pendent factors, followed by Dunnet’s post hoc test.
For colocalization analyses of confocal imaging, we
used an ImageJ 2.0 (NIH, Bethesda, MA, USA) built-in
method [76, 77]. Comparisons of M18L/S colocalizations
across inhibitory versus excitatory compartments were
performed with paired t-tests.
All tests were two-tailed, and p-values < 0.05 were
considered significant. Datasets were analyzed and plot-
ted with JMP 10.0.2 (SAS Institute, Cary, NC, USA),
and/or GraphPad Prism 6.0 (GraphPad Software, La
Jolla, CA, USA).
Additional files
Additional file 1: Figure S1. Immunohistochemical characterization of
Munc18-1 splice variants in human dentate gyrus reveals similar cellular
and subcellular distributions of M18L and M18S than those in rat brain.
Confocal images show a preferential localization of M18L to inhibitory
presynaptic terminals, as its immunofluorescence fully overlaps with that
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of VGAT, but not VGLUT1. M18S shows ubiquitous distribution. Figure S2.
M18L, but not M18S, immunodensity is reduced in the DLPFC of MAP
participants with clinical dementia, compared to those with no or mild
cognitive impairment, as well as in those presenting high burden of
Alzheimer’s disease pathology, using either NIA/Reagan or Braak scales.
(PDF 986 kb)
Additional file 2: Table S1. List of both commercially available and
locally produced primary antibodies used in the present study.
References cited in Table S1 are listed below the table. (PDF 107 kb)
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